A previous in vitro study evaluating PF-04691502 against 33 ovarian cancer cell lines in vitro concluded that sensitivity to the drug did not correlate with PI3 kinase activating mutations or PTEN loss in this disease17. This evidence concerns the gene PTEN and ovarian cancer.